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SUMMARY
Amyotrophic lateral sclerosis (ALS) is a severe neuro-
degenerative disorder without effective neuroprotec-
tive therapy. Known genetic variants impair path-
ways, including RNA processing, axonal transport,
and protein homeostasis. We report ALS-causing
mutations within the gene encoding the glycosyl-
transferase GLT8D1. Exome sequencing in an auto-
somal-dominant ALS pedigree identified p.R92Cmu-
tations in GLT8D1, which co-segregate with disease.
Sequencing of local and international cohorts
demonstrated significant ALS association in the
same exon, including additional rare deleterious mu-
tations in conserved amino acids. Mutations are
associated with the substrate binding site, and
both R92C and G78W changes impair GLT8D1
enzyme activity. Mutated GLT8D1 exhibits in vitro
cytotoxicity and induces motor deficits in zebrafish
consistent with ALS. Relative toxicity of mutations
in model systems mirrors clinical severity. In conclu-
sion, we have linked ALS pathophysiology to in-
herited mutations that diminish the activity of a gly-
cosyltransferase enzyme.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an aggressive and incur-
able neurodegenerative disorder. Progress in understanding of
the pathogenesis of ALS has come primarily from the study of
genetic variants. Approximately 10% of ALS is autosomal domi-
nant but even in sporadic ALS estimates of heritability are as high
as 61% (Al-Chalabi et al., 2010); indeed, genetic mutations iden-
tified in familial ALS patients are often also present in sporadic
ALS patients. Therapeutic targets identified by characterization
of genetic variants, therefore, have the potential to be broadly
applicable. To date, the majority of described genetic variants
are associated with RNA processing, axonal transport, or protein
homeostasis (Kapeli et al., 2017; Chia et al., 2018). Discovery of
an additional genetic variant that highlights upstream disease
biology represents a significant advance.
Using exome sequencing in autosomal dominant familial
ALS cases, we identified heterozygous p.R92C mutations in
glycosyltransfersase 8 domain containing 1 (GLT8D1) that co-
segregate with disease. Targeted sequencing in 103 familial
and young sporadic ALS cases identified five additional patients
carrying two missense mutations within GLT8D1: the p.R92C
mutation identified in the index pedigree and p.G78W. Both mu-
tations lie within exon 4, which encodes the substrate binding
domain of GLT8D1. Sequencing of an international ALS cohort
confirmed significant ALS-association with genetic variation in
exon 4 of GLT8D1 in familial ALS patients, including three addi-
tional rare deleterious missense mutations.
GLT8D1 encodes a glycosyltransferase enzyme of unknown
function, which is widely expressed (http://www.gtexportal.
org/home/). Importantly, this class of proteins has not previously
been associated with neurodegeneration, although GLT8D1 has
been identified as a schizophrenia risk gene (Sasayama et al.,
2014; Yang et al., 2018). It is noteworthy that ALS and schizo-
phrenia share common genetic risk (McLaughlin et al., 2017).
We have localized wild-type and mutant GLT8D1 to the Golgi
apparatus. We have shown that ALS-associated GLT8D1
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Figure 1. Discovery of ALS-Associated Mutations within Exon 4 of GLT8D1 in Close Proximity to the Putative Substrate Binding Site
(A) Original pedigree in which p.R92C mutations were discovered. Exome sequencing was performed in two related individuals with ALS (*). Sanger sequencing
(of red shapes) confirmed the p.R92C mutation is carried by ALS patients (shaded gray) and absent from unaffected individuals.
(B) Rare deleterious mutations identified within exon 4 of GLT8D1.
(C) Phenotype information for patients carrying mutations in GLT8D1 and/or ARPP21.
(legend continued on next page)
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variants are toxic in vivo and in vitro and, moreover, the relative
toxicity of the mutations mirrors the clinical phenotype. Both
knock down and expression of mutated GLT8D1 in zebrafish
embryos produces a locomotor deficit consistent with a role in
motor neuron function. Mutation of GLT8D1 negatively impacts
upon measured glycosyltransferase activity. Taken together,
our data would be consistent with a haploinsufficiency mecha-
nism of toxicity.
RESULTS
Exome Sequencing in an Autosomal Dominant ALS
Pedigree Identifies Candidate Deleterious Variants
Exomesequencing in two related individualswithautosomaldomi-
nant ALS (Figure 1A) identified five potential causal variants.
Candidate monogenic causal variants were shared by both
affected individuals, rare, and predicted deleterious. Variants
were selected for further analysis if the Exome Aggregation Con-
sortium (ExAC) frequency was <1/10,000 controls (Lek et al.,
2016) and the Phred-scaled Combined Annotation Dependent
Depletion (CADD) score was >25 (Kircher et al., 2014). Heterozy-
gous variants in five genes met the filtering criteria: p.R92C (Gen-
Bank: NM_018446: c.274C>T) in GLT8D1, p.P529L (GenBank:
NM_001267619: c.1586C>T) in ARPP21, p.A266T (GenBank:
NM_003848: c.796G>A) in SUCLG2, p.R1252H (GenBank:
NM_173689: c.3755G>A) in CRB2, and p.C116R (GenBank:
NM_052837:c.346T>C) inSCAMP3. Subsequently, another family
member developed unilateral weakness and upper motor neuron
dysfunction suggestive of ALS (Figure 1A). Detailed neurological
investigation did not fulfil El-Escorial diagnostic criteria, but no
alternative cause was identified. Screening this individual for the
five candidate mutations revealed only p.R92C in GLT8D1 and
p.P529L in ARPP21.
Targeted Sequencing Supports Pathogenicity of
Variants within Exon 4 of GLT8D1
Targeted DNA sequencing of the five candidate genes was per-
formed in a cohort of 103 familial and young sporadic ALS cases
from the North of England. The cohort included 34 familial ALS
patients in whom a genetic cause had not been identified despite
screening for ALS-associated mutations in SOD1, C9ORF72,
TARDBP, and FUS; 61 young-onset sporadic ALS patients;
and 13 C9ORF72-ALS patients. SUCLG2, CRB2, and SCAMP3
were not mutated in any additional cases and were excluded
from further analysis. In addition to the two individuals from the
index pedigree, four of the screened patients also carried
p.R92C (GenBank: NM_018446: c.274C>T) within GLT8D1
exon 4 (Figure 1C). Another patient carried a rare deleterious
p.G78W (GenBank: NM_018446: c.232C>A) change within the
same exon of GLT8D1, suggesting a common pathogenic effect
(Figure 1D). Mutations were confirmed by Sanger sequencing by
using independent DNA samples. In addition to an ExAC fre-
quency of <1/10,000 controls, similar mutations are absent
from North of England controls (n = 220) and from unaffected
family members within the index pedigree (Figure 1A). No patient
with a mutation in GLT8D1 carried an additional ALS-associated
mutation, as determined from the ALSOnline Genetics Database
(Abel et al., 2012).
Of the six cases carrying the p.R92C mutation in GLT8D1, five
cases including the two index cases also carried a p.P529L
change (GenBank: NM_001267619: c.1586C>T) within cyclic
AMP (cAMP)-regulated phosphoprotein 21 (ARPP21). In support
of pathogenicity of the p.R92C GLT8D1mutation in the absence
of the ARPP21 variant, one patient carried only the GLT8D1
mutation without an ARPP21 change. Subsequent analysis of
Project MinE whole-genome sequencing data from 4,493 ALS
patients (Project MinE ALSSequencing Consortium, 2018), iden-
tified two additional patients carrying the p.R92C mutation
without a variant in ARPP21. Comparison between the 4,493
Project MinE patients and 60,706 controls sequenced by the
ExAC (http://exac.broadinstitute.org/) revealed that the p.R92C
change is significantly associated with ALS (Fisher exact test,
odds ratio [OR] = 54.1, p = 2.03E-08), and this association re-
mains significant when cases carrying a variant in ARPP21 are
excluded (Fisher exact test, OR = 20.3, p = 0.0029).
Exon 4 of GLT8D1 Is Significantly Enriched with ALS-
Associated Rare Deleterious Variants Affecting
Conserved Amino Acids
Burden analysis was performed using Sequence Kernal Associ-
ation Test-Optimal Unified Test (SKAT-O) (Lee et al., 2012) to
compare rate of genetic variation within exon 4 of GLT8D1 in a
cohort of 1,138 familial ALS patients and 19,450 controls (as
described in Kenna et al., 2016). Rare deleterious variants are
significantly enriched in exon 4 in the familial ALS cohort
(SKAT-O, p = 0.0025); there is no significant ALS-association
within GLT8D1 when exon 4 is excluded (Table S1). Across all
cohorts, we identified five distinct rare deleterious mutations of
GLT8D1 exon 4 in fourteen ALS patients (Figures 1B–1E). Identi-
fication of additional familial ALS cases from an independent
population with similar mutations in GLT8D1 strongly suggests
that GLT8D1 is an ALS gene.
Four of five identified GLT8D1 mutations affect amino acids
that show high evolutionary conservation, as determined by rela-
tive entropy using the NCBI ‘‘Conserved Domains Tool’’ (https://
www.ncbi.nlm.nih.gov/Structure/cdd/cddsrv.cgi) (Figure 1E). All
mutations are closely associated with the proposed GLT8D1
ligand-binding site involving amino acid residues 71–76 (Bourne
and Henrissat, 2001), suggesting that the discovered mutations
may modify this activity.
Clinical Characteristics of Patients with Mutated
GLT8D1
Clinical characteristics of cases carrying a mutation in GLT8D1
are summarized in Figure 1C. Overall, disease characteristics
are within the expected spectrum of ALS (Cooper-Knock et al.,
(D) Identified structural and topological domains within GLT8D1, including the site of identified mutations within exon 4.
(E) Sequence homology analysis within exon 4 localizes ALS-associated mutations to close proximity with the substrate binding site of GLT8D1. ALS-associated
amino acid changes (yellow highlight) affect evolutionary conserved bases (red text) with one exception. Amino acids which form the putative substrate binding
site are indicated (blue highlight). Displayed sequence is glycosyltransferase domain encoded by exon 4 (amino acid [aa] 66–aa116).
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2013). Phenotype data were not available from all cases; how-
ever eight patients with p.R92C mutations suffered a particularly
aggressive disease course with average survival of 21 months,
but patients with p.G78W or p.I70T mutations lived >5 years.
Average age of onset across all patients was 49.3 years, and
three patients developed symptoms in their fourth decade; early
onset is consistent with monogenic disease (Cooper-Knock
et al., 2013).
Synergy between p.P529L ARPP21 and p.R92C GLT8D1
We identified six patients carrying both the p.R92C change in
GLT8D1 and the p.P529L change in ARPP21. Co-segregation
of two rare deleterious mutations is unusual. Within our targeted
sequencing experiment, no other rare SNPs (ExAC frequency,
<0.0001) were shared between individuals who carried both
GLT8D1 and ARPP21 mutations except within the index pedi-
gree. We suggest that both GLT8D1 and ARPP21 changes are
neurotoxic and synergy between them might account for their
Figure 2. When Overexpressed in HEK293
and N2A Cells, GLT8D1 Is Localized to the
Golgi Network and Produces Significant
Toxicity
(A) The Golgi network was imaged in N2A (top) and
HEK293 (bottom) cells using anti-TGN46 (red);
GLT8D1-GFP fusion protein was imaged using
anti-JL8 (green). Nuclear counterstain (Hoechst) is
shown in blue. Scale bar, 50 mm.
(B–E) Overexpression of mutated GLT8D1 in-
creases cytotoxicity (B and C) and reduces
metabolic activity (D and E) in HEK293 (B and D)
and N2A (C and E) cells compared to over-
expression of wild-type protein; all experiments
included 6 biological replicates and either 2 (MTT
assays) or 4 (LDH assays) technical replicates per
biological replicate. *p < 0.05.
Error bars represent mean and SD.
high concurrence in the ALS population.
To support this, we have compiled
phenotype data from ALS patients with
either or both mutations (Figure 1C).
ALS in the context of both mutations is
significantly more severe than in the pres-
ence of either mutation in isolation. Pa-
tients carrying both changes lived
<16months compared to an average sur-
vival of 36 months in ALS patients car-
rying p.R92C-GLT8D1 in isolation and
55 months in the presence of p.P529L-
ARPP21 in isolation (Wilcoxon rank-sum
test, p = 0.001).
GLT8D1 Is Localized to the Golgi
Network in Neuronal and Non-
neuronal Cells
GLT8D1 is expressed in neurons (http://
www.gtexportal.org/home/) and contains
an arginine-lysine motif in its cytoplasmic
domain (Figure 1D), which likely represents a Golgi localization
signal (Uemura et al., 2015). To confirm this, non-neuronal
HEK293 and neuronal N2A cells were transfected with pEGFP-
N1 expression vectors containing the GLT8D1 nucleotide
sequence. Cells were co-stained using anti-JL8 to label GFP-
tagged proteins and anti-TGN46 that is normally localized to
the Golgi network membrane. Confocal microscopy confirmed
significant overlap between GLT8D1 and TGN-46 that supports
localization of GLT8D1 to the Golgi apparatus (Figure 2A). Local-
ization was not altered by expression of R92C or G78W muta-
tions compared to the wild-type protein (data not shown).
Effect of ALS-Associated Mutations of GLT8D1 on Cell
Metabolism and Cell Viability
Mutant and wild-type GLT8D1 were overexpressed in non-
neuronal HEK293 and neuronal N2A cells. 3-(4,5-Dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell prolifera-
tion assays were used to assess metabolic activity; lactate
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dehydrogenase (LDH) quantification was used to assess cell
death. Mutated GLT8D1 was toxic compared to wild-type pro-
tein as measured by both LDH (Figures 2B and 2C; HEK293:
n = 6, ANOVA p = 0.01; N2A: n = 6, ANOVA p = 0.01) and MTT
(Figures 2D and 2E; HEK293: n = 6, ANOVA p = 0.008; N2A:
n = 6, ANOVA p = 0.01) assays. In all cases except theMTT assay
in HEK293 cells, R92C overexpression produced relatively more
toxicity than G78W overexpression, in line with observed relative
clinical severity (Figure 1C). Immunoblotting confirmed equiva-
lent expression of mutated and wild-type proteins (Figure S1).
GLT8D1 Knock Down Leads to Impaired Mobility
of Zebrafish Embryos
Zebrafish larvae behavior was analyzed at 5 days post-fertiliza-
tion following knock down of endogenous glt8d1 by using
splice-blocking antisense morpholino oligonucleotides. Mean
distance moved by 160 zebrafish embryos from three separate
clutch mates was tracked using Viewpoint Zebralab software
(Scott et al., 2016). Knock down of glt8d1 was associated with
a reduction in distance moved by zebrafish (Mann-Whitney
U-test, p < 0.0001) (Figure 3A). No significant non-motor pheno-
type was observed (Video S1). Knock down was confirmed by
RT-PCR (Figure S2).
Overexpression of Mutant GLT8D1 Produces Toxicity
and Impairs Mobility of Zebrafish Embryos Compared to
Wild-Type GLT8D1
Zebrafishembryoswere injectedat theone-cell stagewithmRNA-
encoding human wild-type or mutant forms ofGLT8D1 to investi-
gate the effects of transient gene expression onmotor activity and
Figure 3. Knock Down of GLT8D1 andOver-
expression of Mutant GLT8D1 Produce
Toxicity and Motor Impairment in Zebrafish
Embryos
(A, B, and D) Mean distance moved (mm) during
three light-dark cycles at 5 days post-fertilization
is reduced following injection with 1.5 ng
GLT8D1 splice blocking morpholino (A) compared
to 1.5-ng control morpholino (n = 160 from 3
clutches); and following injection with 1-nl mature
mRNA encoding human GLT8D1-R92C (B) (n = 96
from 2 clutches) or GLT8D1-G78W (D) (n = 48
from one clutch) compared to 1-nl mature mRNA
encoding wild-type human GLT8D1.
(C) Injection of 1-nl mature mRNA encoding hu-
man GLT8D1-R92C significantly reduces survival
of zebrafish embryos at 24 hours and 48 hours
compared to mature mRNA encoding wild-type
human GLT8D1. WT, wild-type; SB, splice block-
ing morpholino. *p < 0.05; **p < 0.01; ****p <
0.0001.
Error bars represent SEM (A, B, and D) or SD (C).
viability. Expression of wild-type GLT8D1,
GLT8D1-R92C, and GLT8D1-G78W pro-
tein was confirmed by immunoblotting
(Figure S2). Zebrafish embryo survival
was reduced in fish exposed to GLT8D1-
R92C compared to wild-type GLT8D1 at
a 1-nl dose (700 pg) (Figure 3C, t test, p = 0.02). Survival was
not significantly impaired with injection of a 0.5-nl (350 pg)
dose (data not shown), but mean distance moved was reduced
at 5 days post-fertilization (Figure 3B, Mann-Whitney U-test,
p = 0.03); to measure movement, ninety-six zebrafish embryos
from two separate clutch mates were tracked. A similar
dose (0.5 nl, 350 pg) of GLT8D1-G78W RNA also reduced
mean distance moved at 5 days post-fertilization (Figure 3D,
t test, p=0.001); forty-eight zebrafishembryos fromasingleclutch
mate were tracked. No significant non-motor phenotype was
observed in any of the tracked fish (Videos S2 and S3).
The Glycosyltransferase Activity of GLT8D1 Is Impaired
by ALS-Linked Mutations
Based on sequence homology, GLT8D1 is amember of glycosyl-
transferase family 8 and exon 4, which contains ALS-associated
mutations and encodes the substrate binding site within the gly-
cosyltransferase domain (Figure 1D). To assess the impact of
discovered mutations on glycosyltransferase activity, we used
a uridine diphosphate (UDP)-Glo glycosyltransferase assay kit
(Promega) with UDP-galactose as substrate.
FLAG-tagged wild-type and mutated GLT8D1-R92C and
GLT8D1-G78W proteins were overexpressed in HEK293 cells
and then immunopurified onto anti-FLAG-coated beads prior
to competitive elution with a 33 FLAG peptide. All three proteins
were purified to a high degree and in equivalent amounts (Fig-
ure 4A). To validate the specificity of the signal, we used miRNA
knock down of expressed GLT8D1 (Figure S1).
In order to measure glycosyltransferase activity, we first deter-
mined the linear range for measurement of UDP concentration
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by the UDP-Glo assay (Figure 4B). Initial reaction velocity was
measured at a fixed enzyme concentration with increasing sub-
strate concentrations. Data were fitted to a standard Michaelis-
Menten equation by nonlinear regression to enable determination
ofmaximalenzymevelocity (Vmax) and theMichaelisconstant (Km)
(Figure 4C). Purified GLT8D1 proteins behaved as expected for
enzymes of this class and were purified in their active forms.
Vmax was reduced 30%–40% (WT: 67.5 mmol/min, G78W:
58.6 mmol/min, R92C: 51.4 mmol/min), and Km was reduced
50% (WT: 3.5 mmol/l, G78W 2.3 mmol/l, R92C 2.5 mmol/l) in
GLT8D1-R92C and GLT8D1-G78W compared to wild-type
enzyme. Similar to our cell-based assays, the relative effect of
the two tested mutations mirrored observed clinical severity,
with R92C producing a more severe phenotype. Next, we fixed
substrate concentration to 5-fold higher than Km in order to
Figure 4. ALS-Linked GLT8D1-R92C Muta-
tion Impairs Glycosyltransferase Activity
(A) FLAG-tagged WT, GLT8D1-G78W, and
GLT8D1-R92C proteins were immunopurified in
1M NaCl-containing buffer to maximize dissocia-
tion of interacting partners and eluted in native
conditions prior to analysis by SDS-PAGE and
Coomassie staining. Input represents 0.1% of
whole-cell protein extracts loaded onto anti-FLAG
coated beads. Arrow indicates FLAG-GLT8D1
proteins.
(B) Standard curve for UDP-Glo assay illustrates
linear correlation for <500 mmol/min UDP.
(C) Initial reaction velocity at fixed enzyme con-
centration with variable substrate concentration;
Michaelis-Menten curves were fitted with nonlinear
regression. WT, wild-type; FT, flow-through.
measure near maximal enzymatic velocity
and plotted enzyme activity as a function
of enzyme concentration. At all enzyme
concentrations, the activity of GLT8D1-
R92C and GLT8D1-G78W proteins was
reduced compared to wild-type enzyme
(Figure S3).
DISCUSSION
To date, understanding and translational
approaches to ALS have been under-
pinned by described genetic variants. In
recent years, these genetic variants
have focused onto a small number of
pathways, including RNA processing,
protein homeostasis, and axonal function
(Kapeli et al., 2017; Chia et al., 2018). This
convergence has limited the new infor-
mation from each discovery. In light of
this, the discovery of a genetic variant
within a novel functional category is ama-
jor step forward for ALS research.
We identified mutations within exon 4
of GLT8D1 that segregated with disease
in an autosomal dominant pedigree. Moreover, we discovered
that there is significant enrichment of GLT8D1 exon 4 mutations
in an international cohort of familial ALS cases compared to
matched controls; this is consistent with a monogenic disease.
Overall, analysis of sequencing data from local and international
cohorts revealed five rare deleterious mutations within GLT8D1
exon 4 in ALS patients.
Based on sequence homology, GLT8D1 is a member of glyco-
syltransferase family 8 and is expected to catalyze the transfer of
a glycosyl group from a donor to acceptor via a ‘‘retaining’’
mechanism involving a glycosyl-enzyme intermediate (http://
www.cazy.org/GT8_structure.html). Although the crystal struc-
ture of GLT8D1 is unknown, it contains a conserved ‘‘DXD’’metal
ion binding site that indicates that it is a Letoir glycosyltransfer-
ase where donor and acceptor binding sites are divided by a
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single ‘‘GT-A’’ fold (Bourne and Henrissat, 2001). Discovered
ALS-associated mutations in GLT8D1 cluster together in a short
sequence of20 amino acids in close proximity to the substrate
binding site, suggesting a common effect on this function.
Consistent with this, we observed a significant reduction in
enzyme activity in mutated GLT8D1-R92C and GLT8D1-G78W
compared to wild-type protein. Measured Km was reduced in
the mutated proteins commensurate with an increase in sub-
strate affinity, which could impair cycling of substrate through
the enzyme and, thus, reduce overall velocity. Moreover, higher
substrate affinity could result in a dominant-negative effect with
a competitive antagonism of wild-type enzyme function. Prece-
dence exists; for example dominant-negative mutations in the
GTPase Ras increase its substrate affinity and, thus, allow it to
act as a competitive antagonist of the wild-type protein (Nassar
et al., 2010). We cautiously note the example of SOD1 mutations
that were originally thought to cause ALS through loss of function
but were subsequently shown to cause gain of function toxicity
(Boille´e et al., 2006); our work awaits validation in a higher organ-
ism. Of note, measured Km valueswere relatively high compared
to reports of other members of the glycosyltransferase 8 family
(Persson et al., 2001), suggesting low substrate affinity. It is
possible that absolute substrate affinity would be higher under
physiological conditions, particularly as the identity of the normal
donor and acceptor for GLT8D1 are unknown and glycosyltrans-
ferase enzymes with a GT-A fold structure have been observed
to show cooperativity between donor and acceptor binding
(Shoemaker et al., 2008). Our reaction conditions utilized UDP-
galactose and occurred without an acceptor.
Our functional data confirm the molecular toxicity of the
discovered mutations in GLT8D1 in vitro and in vivo. In neuronal
and non-neuronal cells, overexpression of mutated GLT8D1 is
toxic compared to equivalent expression of the wild-type pro-
tein. To confirm that GLT8D1 mutations are toxic within a whole
organism, we expressed human mutated and wild-typeGLT8D1
in zebrafish embryos. At higher doses, the expression ofmutated
GLT8D1 produced increased rates of embryo death compared
to wild-type; at lower doses, motor function was specifically
impaired in fish expressing either the GLT8D1-R92C or
GLT8D1-G78W mutated protein. This is consistent with a spe-
cific effect on the motor system. Further supporting a role for
GLT8D1 in motor function, knock down of the endogenous
glt8d1 protein in zebrafish embryos produced a specific deficit
of motor function without observable off-target toxicity. Overlap
between the effect of glt8d1 knock down and overexpression of
mutated GLT8D1 is consistent with a dominant-negative
mechanism.
Clinically, patients carryingmutations inGLT8D1 are within the
spectrum of sporadic ALS, suggesting that they may share a
common disease mechanism. Unfortunately, pathological mate-
rial was not available from these cases and so we were not able
to ascertain the presence of TDP-43-positive neuronal inclu-
sions, which are the hallmark pathology in most cases of ALS.
All patients suffered relatively young-onset disease, which is
consistent with a monogenic disorder. In measures of toxicity
and enzyme activity, the relative severity of the studied muta-
tions mirrored the relative clinical severity—R92C produced a
more severe effect than G78W.
In a number of patients, the p.R92C-GLT8D1 mutation
occurred in the presence of a rare deleterious p.P529L-
ARPP21 mutation. Despite this, our data clearly suggest that
GLT8D1 mutations are toxic in isolation: the p.R92C mutation
is significantly enriched in ALS patients even when patients
also carrying an ARPP21 change are excluded. Moreover, we
observed a significant clustering of five different rare deleterious
mutations within GLT8D1 exon 4 in familial ALS patients, but only
the R92C change occurred in the presence of p.P529L-ARPP21.
Finally, all of our functional data are consistent with a common
effect for two different ALS-associated GLT8D1 mutations:
p.R92C and p.G78W. It is possible that an ARPP21 mutation is
an independent toxic factor that acts synergistically with
GLT8D1 mutation; this might explain their high concurrence in
the ALS population. Consistent with this hypothesis, we have
identified a significant increase in disease severity in ALS pa-
tients carrying both p.R92C-GLT8D1 and p.P529L-ARPP21
compared to either mutation in isolation.
Gangliosides are sialic acid-containing glycosphingolipids
that are particularly abundant within the CNS (Vajn et al.,
2013). Gangliosides within the CNS are typically synthesized in
the endoplasmic reticulum (ER) from a lactosylceramide precur-
sor and are remodeled during transit from the cis-Golgi to the
trans-Golgi network by a series of glycosyltransferase enzymes
that incorporate galactose and GalNAc groups. Consistent
with a role in this process, GLT8D1 shows prominent CNS
expression; moreover, we have shown that GLT8D1 carries a
Golgi localization signal, is prominently expressed within the
Golgi, and is able to accept UDP-galactose as a substrate.
Mature gangliosides are carried to the cell surface where they
function prominently in cell signaling (Yu et al., 2012). Interest-
ingly, autoantibodies against specific gangliosides produce an
inflammatory disease of spinal motor neurons known as multi-
focal motor neuropathy with conduction block (Harschnitz
et al., 2014), which is a common differential diagnosis of ALS.
Altered levels of gangliosides have been reported in animal
models of ALS and in post-mortem CNS tissue from ALS pa-
tients (Dodge et al., 2015; Ariga, 2014). We have shown that
ALS-linked mutations in GLT8D1 impair its glycosyltransferase
activity that we predict will negatively impact on ganglioside
signaling.
In conclusion, we have discovered that mutations in exon 4 of
GLT8D1 are a cause of ALS. GLT8D1 is a glycosyltransferase, a
class of proteins that has not previously been associated with
neurodegeneration. Several lines of our evidence suggest that
ALS-associated mutations are associated with haploinsuffi-
ciency or even a dominant-negative effect: (1) mutations cluster
in proximity to the substrate binding domain, (2) mutated protein
exhibits reduced enzyme activity compared to wild-type, and (3)
overexpression of mutant GLT8D1 and knock down of endoge-
nous glt8d1 in zebrafish both produce a locomotor deficit
consistent with ALS. Classically, pathogenic enzyme mutations
are thought to be recessive, but it is estimated that as many as
25% of enzyme mutations are autosomal dominant (Veitia,
2002) as in our patients. Our discovery places GLT8D1 glycosyl-
transferase activity firmly upstream in the pathogenesis of ALS,
making it an attractive therapeutic target. Currently, we do not
know the extent to which GLT8D1 activity is impaired in ALS
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patients with and without GLT8D1 mutations or whether aug-
menting GLT8D1 activity could be beneficial irrespective of
background activity.
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KEY RESOURCES TABLE
Reagent or Resource Source Identifier
Antibodies
Mouse anti-GLT8D1 GeneTex Cat.# GTX123636; RRID: AB_11169529
Rabbit anti-TGN46 Abcam Cat.# ab50595; RRID: AB_2203289
Mouse anti-Tubulin Sigma-Aldrich Cat.# T6199; RRID: AB_477583
Mouse anti-JL8 Takara Bio Cat.# 632380; RRID: AB_10013427
Mouse anti-FLAG-M2 Sigma Cat.# F3165; RRID: AB_259529
Donkey anti-mouse Alexa568 secondary Life Technologies Cat.# A-10037; RRID: AB_2534013
Donkey anti-mouse Alexa488 secondary Life Technologies Cat.# A-21202; RRID: AB_141607
Goat anti-rabbit Alexa568 secondary Life Technologies Cat.# A-11011; RRID: AB_143157
Donkey anti-rabbit Alexa488 secondary Life Technologies Cat.# A-21206: RRID: AB_141708
Chemicals, Peptides and Recombinant Proteins
Normal goat serum Vector Cat.# S-1000
Fluorescent mounting medium Dako Cat.# GM304
Hoechst 33342 ThermoFisher Scientific Cat.# 62249
Pre-stained protein ladder Cleaver Scientific Cat.# CSL-PPL
Unstained SDS-PAGE Standard Bio-Rad Cat.# 1610317
Bradford reagent Bio-Rad Cat.# 5000001
Clarity Western ECL blotting substrate Bio-Rad Cat.# 1705060S
10x FastDigest Green Buffer ThermoFisher Scientific Cat.# B72
Trypsin Sigma-Aldrich Cat.# 59427C
Thiazolyl Blue Tetrazolium Bromide (MTT) Sigma-Aldrich Cat.# M2128
opti-MEM ThermoFisher Scientific Cat.# 11058021
Laemmli buffer Bio-Rad Cat.# 1610747
SigmaFASTTM Protease Inhibitor Cocktail
tablets
Sigma-Aldrich Cat.# S8820
Lysogeny broth ThermoFisher Scientific Cat.# 10855021
LB agar ThermoFisher Scientific Cat.# 22700025
b-mercaptoethanol Sigma-Aldrich Cat.# M6250
Triton X-100 Sigma-Aldrich Cat.# X100
Hygromycin B Invitrogen Cat.# 10687010
Blasticidin ThermoFisher Scientific Cat.# A1113902
Penicillin-Streptomycin Sigma-Aldrich Cat.# P4333
DMF Fisher Scientific Cat.# D/3840/17
SDS Fisher Scientific Cat.# S/5200/53
SDS - Lauryl Sulfate Melford Cat.# L22010-1000
Sodium chloride 99.5% Fisher Scientific Cat.# S/3161/65
EDTA Sigma-Aldrich Cat.# E5134
DTT Sigma-Aldrich Cat.# D9779
HEPES Sigma-Aldrich Cat.# H3375
Glycerol Sigma-Aldrich Cat.# G9012
Manganese (II) chloride Fisher Scientific Cat.# M/1850/53
1M Tris buffer Vivantis Cat.# PB0855-1L
Dulbecco’s Modified Eagle’s Medium
(DMEM)
Corning Cat.# 10-017-CV
Tetracycline-free FBS Biosera Cat.# FB-1001T
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact,
Dr. Johnathan Cooper-Knock (j.cooper-knock@sheffield.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Selection of patients and controls for genetic sequencing
The study was approved by the South Sheffield Research Ethics Committee and informed consent was obtained for all samples.
Genomic DNA was extracted from 103 ALS patients (33 female, 65 male, 5 unavailable) from the North of England. In this cohort
Continued
Reagent or Resource Source Identifier
FBS ThermoFisher Scientific Cat.# 10270106
BSA Sigma-Aldrich Cat.# A2058
Agarose Melford Cat.# MB1200
3x FLAG peptide Sigma-Aldrich Cat.# F4799
Anti-FLAG M2 magnetic beads Sigma-Aldrich Cat.# M8823
Critical Commercial Assays
mMESSAGE mMACHINE-SP6
transcription kit
Fisher Scientific Cat.# AM1340
LDH Cytotoxicity Assay Kit Pierce Cat.# 88953
UDP-glycosyltransferase assay Promega Cat.# V6961
UDP-galactose 100mM Promega Cat.# V7071
Experimental Models: Cell Lines
HEK293T ATCC Cat.# ACS-4500
HEK293 FlpIN Invitrogen Cat.# R75007
N2A ATCC Cat.# CCL-131
HEK293 ATCC Cat.# CRL-1573
Experimental Models: Organisms/Strains
Zebrafish AB zebrafish zfin.org/ZDB-GENO-960809-7
Oligonucleotides
See Table S2 for oligo information
Recombinant DNA
pcDNA5/FRT/TO_GFP vector Addgene Cat.# 19444; RRID: Addgene_19444
pcDNA6.2-GW/EmGFP vector ThermoFisher Scientific Cat.# K493600
Software and Algorithms
SKAT-O Lee et al., 2012 http://cran.r-project.org/web/packages/
SKAT/index.html
R The R Project for Statistical Computing http://cran.r-project.org/mirrors.html
Galaxy The Galaxy Project https://usegalaxy.org/
snpStats University of Cambridge http://www.bioconductor.org/packages/
release/bioc/html/snpStats.html
VariantAnnotation Obenchain et al., 2014 http://www.bioconductor.org/packages/
release/bioc/html/VariantAnnotation.html
Plink Purcell et al., 2007 http://zzz.bwh.harvard.edu/plink/
download.shtml
PRISM 7 GraphPad https://www.graphpad.com/
Zebralab Viewpoint http://www.viewpoint.fr/en/p/software/
zebralab
Fiji (Fiji Is Just ImageJ) NIH https://imagej.net/Fiji
wANNOVAR Yang and Wang, 2015 http://wannovar.wglab.org/
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mean age of onset was 49 years andmean survival (censored) was 67months. The cohort included 34 familial ALS patients in whoma
genetic cause had not been identified despite screening for ALS associated mutations in SOD1, C9ORF72, TARDBP, and FUS; and
61 young-onset sporadic ALS patients. Two additional cohorts of patients were utilized for genetic screening: the Project MinE latest
data freeze including 4493 ALSpatients and 1924 controls (3764males and 2632 females, 21 unavailable); and the ALS Variant Server
familial ALS cohort (http://als.umassmed.edu/index.php#FALSbrowser, no phenotype information available) including 1138 familial
ALS patients.
Immortalized cell lines
Human embryonic kidney-293 (HEK293) cells and mouse neuro-2A (N2A) cells were cultured in DMEM medium supplemented with
10% (v/v) fetal bovine serum (Thermo-Fisher Scientific), 50 units/mL of penicillin and 50 mg/mL of streptomycin. N2A cell media was
supplemented with an additional 500 mM sodium pyruvate (Thermo-Fisher Scientific). Cell lines were maintained at 5% CO2 in a
37C incubator and split when80% confluent. All experimental work was performed using HEK293T and N2A cells within the range
of 7-32 passages.
Zebrafish models
All applicable international, national and/or institutional guidelines for the care and use of animals were followed. This includes review
by the local ethical review panel at the University of Sheffield, UK. Zebrafish of the AB strain were raised in recirculating systems pro-
vided by Techniplast, at a density of 1 zebrafish per 0.25 l. Water was maintained at pH 7.4, a temperature of 28C, and electrolytic
conductivity of 500 mS/cm. Zebrafish were exposed to 14 hour light and 10 hour dark cycles. The night before breeding, adult male
and female zebrafish were transferred to breeding tanks, separated by a clear plastic divider. At the start of the light cycle the
following day, the dividers were removed and eggs were collected. Embryos were transferred to Petri dishes containing fresh E3me-
dia and incubated at 28C.
METHOD DETAILS
High Throughput DNA sequencing
Exome sequencing was performed by Oxford Gene Technology (https://www.ogt.com/). Genomic DNA was enriched by SureSelect
All Exon V4 capture in prepare libraries. Sequencing was performed using an Illumina HiSeq 2000 with 100bp paired end reads and
minimum 50X coverage.
For targeted validation of candidate genes genomic DNA was enriched for selected genes using a custom designed Agilent Sure-
Select in solution kit. Sequencing was performed using an Illumina HiScan platform according to manufacturer’s instructions.
All sequencing data was aligned using Galaxy (http://usegalaxy.org). Reads were mapped to the human genome assembly
GRCh37 (hg19) reference genome using BWA (Li and Durbin, 2009). GATK (McKenna et al., 2010) was used to produce vcf. files
which were annotated using wANNOVAR (Yang and Wang, 2015).
Generation of GFP and FLAG-tagged GLT8D1 plasmids
For GFP-tagged fusions, the humanGLT8D1 open reading frame (IMAGE:40116197) was amplified using oligonucleotides G8-1-koz-
NheI5 and G8-371-XhoI3 (Table S2) and cloned as a NheI/XhoI PCR fragment into the NheI/XhoI restriction sites of the pEGFP-N1
vector (Clontech) to generate pEGFP-N1 _GLT8D1-eGFP.
For FLAG-tagged fusions, BamHI/HindIII restricted oligonucleotides (Table S2) bearing Kozac and 3xFLAG-M2 tag sequences
were annealed and phosphorylated prior to cloning into the HindIII/BamHI sites of the backbone pcDNA5/FRT/TO_GFP vector
(Addgene 19444) to generate a pcDNA5/FRT/TO_3xFLAG vector. TheHindIII site of pcDNA5/FRT/TO_3xFLAGwas further destroyed
by site-directed mutagenesis. The humanGLT8D1 open reading frame (IMAGE:40116197) was amplified using oligonucleotides G8-
1-BclI5 and G8-371stp-XhoI3 (Table S2) and cloned as a BclI/XhoI PCR fragment into the BamHI/XhoI restriction sites of the
pcDNA5/FRT/TO_3xFLAG vector to generate pcDNA5/FRT/TO_3xFLAG-GLT8D1.
G78W and R92C ALS-linked mutations were introduced on the pEGFP-N1 _GLT8D1-eGFP and pcDNA5/FRT/TO_3xFLAG-
GLT8D1 plasmids by site-directed mutagenesis using the following oligonucleotides: G8-G78W_QC_fwd and G8-G78W_QC_rev;
or G8-R92C_QC_fwd andG8-R92C_QC_rev (Table S2). All plasmids were validated by Sanger-sequencing and sequences are avail-
able upon request.
MTT assays
HEK293 and N2A cells were transfected with pEGFP-N1 vectors expressing wild-type and mutant GLT8D1 sequences. Control
groups were transfected with empty pEGFP-N1 vectors. A colorimetric assay using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetra-
zolium bromide (MTT) dye was used to assess N2A and HEK293 cellular metabolic activity at 2 and 3 days post transfection (dpt),
respectively. 55 mL of 5mg/mL of MTT reagent in PBS was added per well of a 24-well culture plate and incubated at 37C for 1 hour.
550 mL of un-precipitated 20%SDS in 50% di-methyl formamide (DMF) + dH2O (pH 7.4) was added per well andmixed thoroughly to
lyse the cells. Cells were incubated in a dark environment on an orbital shaker for 1 hour. The colorimetric change was measured
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using a PHERAstar FS spectrophotometer (BMG Biotech), and absorbance readings taken at 590nmwere normalized to media-only
wells. Mean absorbance readings were calculated for each biological repeat and expressed as a percentage of controls.
LDH assay
HEK293 and N2A cells were transfected with pEGFP-N1 vectors expressing wild-type and mutant GLT8D1 sequences. Control
groups were transfected with empty pEGFP-N1 vectors. The lactate dehydrogenase (LDH) assay was used to quantify the amount
of LDH released into the culture media from HEK293 and N2A cells at 2 and 3 dpt, respectively. A PierceTM LDH Cytotoxicity Assay
Kit (ThermoFisher Scientific) was used according to the manufacturer’s instructions. Sterile, ultra-pure H2O was added to one set of
triplicate cell-containing wells (10% v/v) as a measure of spontaneous LDH activity. 10x Lysis buffer was added to another
set of triplicate cell-containing wells (10% v/v) to determine the maximum LDH activity. Cells were incubated at 37C in 5% CO2
for 45 minutes. 50 mL of each sample medium was transferred to an optically clear 96-well plate in triplicate wells. 50 mL of reaction
mixture (lyophilizate, 11.4mL ultra-pure H2O, 0.6mL assay buffer) was added to each sample well and plates were incubated in a dark
environment for 30 minutes. 50 mL of stop solution was added to each sample well and the absorbance was measured at 490nm to
680nm using a PHERAstar FS spectrophotometer (BMG Biotech). The 680nm absorbance value was subtracted from the 490nm
absorbance value to determine LDH activity. Mean absorbance readings were calculated for each biological repeat and expressed
as a percentage of controls.
Zebrafish
Splice-blocking morpholino and control morpholino oligonucleotides (Table S2) were designed and provided by Gene Tools, LLC.
The GLT8D1 start codon lies within exon 2, therefore skipping this exon was considered likely to change expression of the gene.
The splice blocking morpholino sequence complementary to the splice junction target from 50 - 30 is shown in bold; brackets have
been inserted either side of the pre-mRNA (sense strand) target to illustrate its position in the sequence:
ACATCAGAGTCTGCATACCTGAAGT[ACGCAGAGgtaactatattttacac]gactttca.
Morpholino powder was reconstituted in sterile Milli-Qwater and 1%phenol red to create a 1mMstock. Reduction in expression of
the zebrafish glt8d1 mRNA was confirmed by RT-PCR.
For overexpression studies, the human GLT8D1 sequences were cloned into PCS2+ downstream of an SP6 promotor and con-
tained a 30 polyA signal. Plasmids were amplified by transformation of DH5-a competent Escherichia coli cells before overexpression
in zebrafish embryos. mRNA was synthesized using mMessage machine (Fisher scientific) as per manufacturer’s protocol, purified
and resuspended in RNase free water.
Fertilized embryos were injected into the yolk at the one-cell stage using a pressure injector with either 0.5nL, 1.0nL or 2.0nL of
injection material. Embryos were transferred to Petri dishes containing E3 media. Any unfertilized embryos, or embryos damaged
during the injection process, were discarded. To increase the reliability of data, zebrafish embryos from separate clutch mates un-
derwent the same injection process for each biological repeat. Embryos were raised to 2 days for western blotting for detecting
reduction in expression levels and to 5 dpf for behavioral analysis.
Viewpoint Zebralab software was used to record the activity of individual larva in a 96-well plate at 5 days post-fertilization. Zebra-
fish embryoswerewashed in fresh E3media (approximately 50 embryos per group) and transferred to an optically clear 96-well plate,
one fish per well in 200 mL E3 medium. 100 mL of E3 media was removed from one column and replaced with 100 mL of Tricaine to
create a non-motile control group. Fishwere left to acclimatise to the 96-well plate for 30minutes. Zebrafishwere then placed inside a
Zebrabox observation chamber (Viewpoint) and were habituated at 10% light intensity for 30 minutes prior to behavioral testing.
Zebrafish were exposed to a 10 minute light (10% intensity) cycle followed by a 10 minute dark (0% intensity) cycle. These cycles
were then repeated to equal a total of 40 minutes of video recording. Motor function was analyzed according to the mean distance
traveled.
For immunoblotting: Dechorionated zebrafish embryos (2dpf) were transferred to eppendorf tubes (20 embryos per tube) contain-
ing 1mL E3 media (34.8g NaCl; 1.6g KCl; 5.8g CaCl2$2H2O; 9.78 g MgCl2$6H2O) and immersed in Tricaine (MS222) (400mg tricaine
powder; 97.9mL dH2O; 2.1mL 1 M Tris; pH 7) (Sigma-Aldrich) (164 mg/L) for 5 minutes. E3 media was removed and replaced with
1 mL/embryo 2x Laemmli buffer (65.8 mM Tris HCl; 26.3% (w/v) glycerol; 2.1% SDS; 0.01% bromophenol blue; 355 mM 2-mercap-
toethanol; pH 6.8). Zebrafish embryos were lysed by sonication (Soniprep 150, MSE) for 10 s at 25% amplitude followed by a 30 s
incubation on ice; this process was repeated 3 times for each group. Embryos were subsequently boiled at 95C for 10 minutes, then
centrifuged at 10,000 xg for 3 minutes. 10 mL of lysate was added per lane and fractionated on a 12% SDS-PAGE gel.
Immunocytochemistry
HEK293 and N2A cells were transfected with pEGFP-N1 vectors expressing wild-type andmutant GLT8D1 sequences. HEK293 and
N2A cells were cultured on sterile coverslips in 24-well plates for 2/3 days prior to staining, respectively. Cells were blocked using 5%
normal goat serum (NGS) (v/v%) in PBS with 0.01% TritonTM X-100 (v/v%), and were incubated at room temperature for 45 minutes.
Blocking buffer was removed and cells were incubated in primary antibody, diluted in 5%NGS (v/v%), at room temperature for 1 hour
or overnight at 4C. Cells were washed 3x in PBS (5minutes per wash), then incubated in a fluorescent secondary antibody, diluted in
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5% NGS (v/v %), in a dark environment at room temperature for 1 hour. Cells were incubated with a nuclear counterstain (Hoechst
33342) in the dark for 5 minutes at room temperature and washed 3x with PBS (5 minutes per wash). Coverslips were mounted onto
microscope slides using fluorescencemountingmedium (DAKO) and stored in a dark environment at 4Covernight to dry. Cells were
imaged the following day using a using a Leica SP5 confocal microscope system with a 3 63/1.4 oil immersion objective lens.
Immunoprecipitation and assessment of glycosyltransferase activity
HEK293 and N2A cells were transfected with pcDNA5/FRT/TO_3xFLAG vectors expressing mutant and wild-type GLT8D1. Cells
were lysed 2 dpt in lysis buffer (150mM NaCl, 1mM EDTA, 1mM DTT, 0.5% Triton X-100, 50mM HEPES, 10% glycerol, pH 7.5)
and a Bradford assaywas used to determine overall protein concentration. Protein lysates were incubated with anti-FLAGM2mag-
netic beads (Sigma-Aldrich) for 4 hours on a rotating mixer at 4C. FLAG-tagged GLT8D1 was eluted overnight in lysis buffer using a
3xFLAG peptide (Sigma-Aldrich). Protein purification was confirmed via a combination of Coomassie Blue staining and immuno-
blotting. To validate the specificity of GLT8D1 immunoblot bands we performed miRNA knockdown of expressed GLT8D1. miRNA
sequences against human GLT8D1 (NCBI Reference Sequence: NM_152932.2, transcript variant 1) were designed using the ‘miR
RNAi’ Block-IT RNAi designer tool (ThermoFisher): GLT8D1_miR1 target: ATTGTAGGGCCTCAACCTATA starts at 241nt,
GLT8D1_miR2 target: GAGCAGGAAACCAGTACAATT starts at 749nt, GLT8D1_miR3 target: TTTGTAAAGGCTGCCAAGTTA starts
at 1075nt. Synthesized oligonucleotides (Table S2) were annealed and ligated into pcDNA6.2-GW/EmGFP vectors. HEK293 cells
were co-transfected with pcDNA5/FRT/TO_3xFLAG vectors expressing wild-type GLT8D1 with and without pcDNA6.2-GW/EmGFP
vectors expressing miRNA sequences. Knockdown was confirmed at two days post transfection via immunoblotting.
Glycosyltransferase activity was measured using a UDP-Glo Glycosyltransferase Assay kit (Promega) according to the manufac-
turer’s instructions. 25 mL reactions were initiated by adding 28mg/mL of purified protein in lysis buffer to a UDP-galactose substrate
(Promega) in 3 mL 1x glycosyltransferase reaction buffer (50mM Tris pH 7.5 + 5mM MnCl2) + dH2O. Reactions were assembled in a
solid white 96-well plate at room temperature and incubated at 37C for 60 minutes. To determine kinetic parameters of the glyco-
syltransferase enzyme, multiple reactions with varying concentrations of either the enzyme or substrate were carried out simulta-
neously in the presence of fixed volumes of all other components. Glycosyltransferase reactions were terminated by the addition
of 25 mL UDP detection reagent to each well of the assay plate. Plates were mixed for 30 s on a shaker and incubated in a dark envi-
ronment at room temperature for 60 minutes. Luminescence was recorded using a Pherastar FS system (BMG Labtech). A standard
curve of 0-25 mMUDP-standard was prepared in 1x glycosyltransferase reaction buffer to determine the relationship between [UDP]
and luminescence measurement.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was conducted in GraphPad Prism 7 (La Jolla, CA). All bar graphs show the mean ± SEM. Data comparing two
variables was transformed to identify outliers and analyzed to identify statistical differences between the treatment groups. Statistical
test used was a non-parametric analysis of variance (ANOVA) except zebrafish data which were analyzed using either a Mann-Whit-
ney test or, in the case of survival data, a paired t test to account for continuity between time points.
Genetic burden analysis to determine the relative frequency of rare deleterious variants within exon 4 of GLT8D1 was performed
using SKAT-O (Lee et al., 2012). Rare deleterious mutations were defined by frequency within the ExAC dataset of < 1/10,000 control
alleles (Lek et al., 2016), and a Phred-scaled Combined Annotation Dependent Depletion (CADD) score > 25 (Kircher et al., 2014)
based on the minimum score seen in ALS patients. For burden analysis, threshold CADD score was determined by the minimum
seen in patients. Comparison of various pathogenicity prediction tools recently supported the sensitivity and specificity of CADD
(Salgado et al., 2016). Given that we were focused on exonic changes with an effect on protein function, synonymous changes
were excluded. We also excluded short indels and changes with a read depth < 10 due to the possibility that these represent
sequencing errors; we validated GLT8D1 mutations by Sanger sequencing.
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